Press release -

Atherosclerosis vaccine study wins VINNOVA grant

Athera Biotechnologies has been granted support from the Swedish Governmental Agency for Innovation Systems, VINNOVA, for a pre-study to investigate a new approach with vaccination to prevent atherosclerosis.

Three hundred companies had applied for the current call to the Research&Growth program to a total amount of SEK 440 million. VINNOVA has today announced the 49 companies of these 300 which are supported with in total SEK 50 million. Athera Biotechnologies is among the seven grant winners who are involved in the life science industry.

Through the Research&Growth program, VINNOVA finances research and development projects in small companies. Companies can apply for support for research and development projects, pre clinical trials or necessity identification before research and development projects.

Topics

  • Health, Health Care, Pharmaceuticals

Categories

  • athera biotechnologies
  • athera
  • atherosclerosis
  • läkemedel

About Athera Biotechnologies AB

The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of cardiovascular disease. Athera´s focus is on ATH3G10, a clinical stage biopharmaceutical program with block-buster potential. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB.For more information: www.athera.se

Contacts

Carina Schmidt

Press contact Senior Business Advisor, M.Sc. Senior Business Advisor, M.Sc. +46 (0)76-1938190

Related media

  • Athera Biotechnologies
  • License: Media Use
    The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
Download

Related content

Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease

Richter-Helm and Athera have signed an agreement for the development and manufacturing of Athera’s novel product for prevention of plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium. The recombinant protein Annexin A5 is intended for the treatment of patients with Acute Coronary Syndrome and who are at imminent risk for Myocardial Infarction.